Down Syndrome Cell Models for Research

Down syndrome (DS) is the most common chromosomal disorder, occurring in approximately 1 in 700 live births worldwide (WHO, 2023). The global prevalence is estimated at 1 in 1,000 live births, with over 6 million individuals living with DS. The condition is characterized by intellectual disability, distinct facial features, and increased risk for congenital heart defects, Alzheimer's disease, and leukemia. Life expectancy has improved dramatically, from 25 years in 1983 to over 60 years today (NCI, 2023). The economic burden is substantial, with lifetime costs estimated at over $1 million per individual (CDC, 2023).

DS is a powerful model for studying gene dosage effects, developmental biology, and neurodegeneration. The extra copy of chromosome 21 leads to overexpression of over 200 genes, providing a unique opportunity to investigate gene-dosage imbalances. Research focuses on understanding the molecular basis of intellectual disability, Alzheimer's disease pathology, and cancer susceptibility. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Down Syndrome Research and Treatment Foundation, provide valuable resources for identifying dosage-sensitive genes and pathways. Open questions include the role of specific genes in cognitive impairment and the development of targeted therapies.

The pathogenesis of DS involves dysregulation of multiple pathways due to trisomy 21. Key pathways include:

• • Neurodevelopmental pathways: Overexpression of DYRK1A and RCAN1 disrupts neuronal proliferation and differentiation, leading to intellectual disability.
• • Alzheimer's disease pathway: Overexpression of APP leads to increased amyloid-beta production, causing early-onset Alzheimer's disease.
• • Cancer pathways: Overexpression of oncogenes like ETS2 and RUNX1 increases risk of leukemia, while tumor suppressors like DSCR1 may have protective effects.
• • Mitochondrial dysfunction: Overexpression of SOD1 and other genes leads to oxidative stress and mitochondrial dysfunction.

Data from TCGA and COSMIC (2023).

Trisomy 21 disrupts several signaling networks:

• • MAPK/ERK pathway: Overexpression of DYRK1A and other genes hyperactivates the MAPK pathway, affecting cell proliferation and differentiation.
• • PI3K/AKT pathway: Altered expression of PTEN and other regulators leads to abnormal cell survival and growth.
• • Wnt pathway: Overexpression of DSCR3 and other genes modulates Wnt signaling, impacting neurodevelopment.
• • NFAT pathway: RCAN1 overexpression inhibits calcineurin, reducing NFAT activity and affecting immune function and cardiac development.

Organoids derived from trisomy 21 iPSCs recapitulate early brain development and are valuable for studying neurodevelopmental defects.

• • Ts65Dn mouse: Most widely used DS model, segmental trisomy of chromosome 16.
• • Tc1 mouse: Transchromosomic mouse carrying human chromosome 21.
• • Dp(16)1Yey mouse: Duplication of the entire mouse chromosome 16 region homologous to human chromosome 21.
• • PDX models: Patient-derived xenografts for leukemia and other cancers associated with DS.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise gene edits to model DS. For example, knocking out DYRK1A in a trisomy 21 iPSC line can help dissect its contribution to cognitive deficits. Similarly, introducing the APP Swedish mutation into a normal cell line can model Alzheimer's disease pathology. Commercially available, sequence-verified gene-edited cell lines (e.g., DYRK1A knockout, APP knock-in) accelerate research by providing reproducible models. These are available from commercial sources and are validated for off-target effects and karyotype stability.

Gene-edited cell lines are used to validate the function of genes on chromosome 21. For example, knocking out DYRK1A in trisomy 21 neurons rescues synaptic deficits, confirming its role in intellectual disability. Similarly, APP knock-in lines demonstrate the direct effect of APP overexpression on amyloid-beta production, providing a platform for testing anti-amyloid therapies.

Isogenic pairs (e.g., trisomy 21 vs. disomy 21) are used in high-throughput screens to identify compounds that selectively target trisomy 21 cells. For example, screening for drugs that inhibit DYRK1A has identified potential cognitive enhancers. Resistance models can be generated by exposing cells to increasing drug concentrations, allowing the study of resistance mechanisms.

CRISPR screens using gene-edited cell lines can identify synthetic lethal interactions. For example, knocking out RCAN1 in trisomy 21 cells may reveal vulnerabilities that can be targeted therapeutically. Such screens also help identify biomarkers for early detection of DS-associated leukemia.